Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

To increase its global CDMO capabilities in the development and manufacturing of large molecules for human clinical trials, Piramal Pharma has invested INR 101.77 crore ($13.47 million) for a 27.78% equity stake in Yapan Bio.

Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.

Investing in the company is regarded by Piramal as a shrewd move given the speed at which the biologics segment of the pharmaceutical industry is growing.

"During the past decade, biologics and their accompanying development services are the fastest growing segments of the CDMO market," said Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited.

Already, Yapan Bio has earned revenues of INR 11.8 cr ($1.56 million) for H1FY22 and is poised for fast growth in response to strong market demand.

Piramal Pharms Solutions currently offers integrated payload, conjugation and fill/finish services. The biologics capabilities of Yapan Bio can be synergistic with Piramal Pharms Solutions' antibody drug conjugation capabilities, particularly for customers who prefer the speed and simplicity of an integrated programme that involves development, manufacturing, conjugation, and fill/finish.

ABOUT PIRAMAL PHARMA SOLUTIONS

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.